Small Parkinson's Trial Links Psilocybin to Reduced Inflammatory Markers
In a small nonrandomized trial, psilocybin therapy was associated with lower systemic inflammation in Parkinson's patients who had mood dysfunction. An inflammation index remained lower than baseline through 30 days, but a mitochondrial stress marker fell only briefly. The researchers said larger randomized controlled trials are needed to confirm the results.
The open-label study enrolled 12 adults aged 40–75 with mild-to-moderate Parkinson’s disease. Participants received synthetic psilocybin by mouth at 10 mg and 25 mg roughly two weeks apart; plasma samples came from nine people at baseline, one day after each dose, and 30 days after the higher dose.
Researchers measured a proinflammatory index averaging standardized levels of IL-6, IL-8, TNF-alpha, interferon gamma, and high-sensitivity C-reactive protein. They also tracked GDF-15 and FGF-21 as mitochondrial stress markers. The report is described as the first such marker analysis after psychedelic treatment in a neurodegenerative disease.
If confirmed, these findings could encourage broader research into psychedelic-assisted treatment for neurodegenerative conditions, potentially affecting Parkinson’s patients with mood symptoms and their caregivers by expanding therapeutic options. Clinicians and regulators may face questions about evidence strength, safety, and access, while patient groups may call for more trials. For now, the small, nonrandomized design means any societal effect is likely to remain indirect, shaping research priorities and public discussion rather than clinical practice.